Danaher Co. (NYSE:DHR) Shares Acquired by Parisi Gray Wealth Management

Parisi Gray Wealth Management lifted its stake in shares of Danaher Co. (NYSE:DHR) by 4.0% during the 4th quarter, HoldingsChannel reports. The firm owned 14,151 shares of the conglomerate’s stock after purchasing an additional 541 shares during the quarter. Danaher comprises 1.3% of Parisi Gray Wealth Management’s investment portfolio, making the stock its 18th biggest position. Parisi Gray Wealth Management’s holdings in Danaher were worth $3,274,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. DHJJ Financial Advisors Ltd. purchased a new stake in Danaher in the third quarter valued at approximately $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher in the fourth quarter valued at $27,000. OFI Invest Asset Management acquired a new stake in shares of Danaher in the third quarter valued at $30,000. First Capital Advisors Group LLC. acquired a new stake in shares of Danaher in the second quarter valued at $32,000. Finally, BOK Financial Private Wealth Inc. acquired a new stake in shares of Danaher in the third quarter valued at $34,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DHR shares. Barclays cut Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 price target on the stock. in a research note on Wednesday, January 24th. Citigroup raised their price target on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. JPMorgan Chase & Co. raised their price target on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $266.00.

Danaher Trading Up 0.1 %

DHR stock traded up $0.27 during midday trading on Thursday, hitting $249.04. The stock had a trading volume of 113,513 shares, compared to its average volume of 2,725,729. The firm has a market cap of $184.21 billion, a PE ratio of 38.94, a price-to-earnings-growth ratio of 3.77 and a beta of 0.84. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The company’s 50-day moving average price is $246.68 and its 200 day moving average price is $230.40.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. Danaher’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.87 EPS. On average, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s payout ratio is currently 15.02%.

Insider Activity

In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock valued at $8,265,802 in the last ninety days. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.